Form 4: bluebird bio CEO Andrew Obenshain Reports Equity Conversion Following Merger Completion

bluebird bio's President and CEO, Andrew Obenshain, reported the conversion of his equity holdings into cash and contingent value rights as part of the company's acquisition by Beacon Parent Holdings, L.P.

Summary

• Andrew Obenshain, President and CEO of bluebird bio, Inc., reported transactions related to the company's merger with Beacon Parent Holdings, L.P.
• The merger, effective June 2, 2025, resulted in bluebird bio becoming a wholly owned subsidiary of Beacon Parent Holdings, L.P.
• As part of the merger agreement, outstanding time-based restricted stock unit (RSU) awards and performance-based restricted stock unit (PSU) awards held by Mr. Obenshain were accelerated, fully vested, and converted.
• RSU awards were converted into a right to receive $3.00 in cash plus one contingent value right (CVR) per share, with each CVR representing a right to receive $6.84 in cash upon achievement of a specified milestone.
• PSU awards were converted under similar terms, with performance goals deemed achieved at the greater of target and actual levels.
• Specifically, Mr. Obenshain disposed of 9,300 shares of Common Stock on June 2, 2025, representing the conversion of RSU awards.
• He also acquired and immediately disposed of 14,820 shares of Common Stock on June 2, 2025, representing the vesting and subsequent conversion of PSU awards.

Sentiment

Score: 5

Explanation: Neutral. This is a factual report of a completed corporate action (merger) and the subsequent conversion of insider equity holdings, not an operational update or a new strategic announcement.

Positives

• The reporting person's equity awards (RSUs and PSUs) were accelerated and fully vested as part of the merger agreement.
• Holders of equity, including the CEO, received a defined cash consideration ($3.00 or $5.00 per share) and potential additional value through Contingent Value Rights ($6.84 per CVR) as part of the acquisition.

Negatives

• bluebird bio, Inc. ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary, which means its common stock is no longer traded.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to the achievement of specified milestones, meaning the $6.84 payment is not guaranteed.

Future Outlook

The document primarily reports on a completed merger and related equity conversions, thus it does not provide forward-looking statements regarding the future operations or financial performance of the now-private entity.

Industry Context

This filing reflects a consolidation event within the biotechnology or pharmaceutical industry, where a publicly traded company (bluebird bio) is acquired by a private entity (Beacon Parent Holdings, L.P.). Such mergers are common strategies for companies seeking to streamline operations, gain market share, or for private equity firms to acquire assets.

Related Party Transactions

• The entire transaction (merger) is effectively a related party transaction once bluebird bio becomes a wholly owned subsidiary of Parent. The conversion of equity awards is part of this transaction.

Stakeholder Impact

• Shareholders: Public shareholders of bluebird bio, Inc. received cash and/or CVRs in exchange for their shares, and the company's stock is no longer publicly traded.
• Employees: The document indicates that equity awards (RSUs, PSUs) held by employees (specifically the CEO) were converted, implying a change in the compensation structure for equity holders post-merger.

Key Dates

Keywords

bluebird bio, BLUE, Andrew Obenshain, SEC Form 4, insider transaction, merger, acquisition, tender offer, restricted stock units, RSU, performance stock units, PSU, contingent value rights, CVR, Beacon Parent Holdings, L.P.